Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 198Leukemia, Lymphocytic, Chronic, B-Cell 48Myelodysplastic Syndromes 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Recurrence 27Leukemia 26Lymphoma, Mantle-Cell 22Leukemia, Myelomonocytic, Chronic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Biphenotypic, Acute 15Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasm, Residual 9Hematologic Neoplasms 9Multiple Myeloma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Leukemia, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × venetoclax × Clear all
NCT04543916 2021-03-03

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Virginia Commonwealth University

Phase 1/2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡